SAVA vs. ORGO, CMPX, AKBA, PRTC, ALT, CDXC, KMDA, MREO, ERAS, and TKNO
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Organogenesis (ORGO), Compass Therapeutics (CMPX), Akebia Therapeutics (AKBA), PureTech Health (PRTC), Altimmune (ALT), ChromaDex (CDXC), Kamada (KMDA), Mereo BioPharma Group (MREO), Erasca (ERAS), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry.
Cassava Sciences vs.
Organogenesis (NASDAQ:ORGO) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
Cassava Sciences received 1 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.44% of users gave Organogenesis an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote.
In the previous week, Cassava Sciences had 1 more articles in the media than Organogenesis. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.
Organogenesis has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by insiders. Comparatively, 9.0% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Organogenesis currently has a consensus target price of $5.00, indicating a potential upside of 47.93%. Cassava Sciences has a consensus target price of $111.50, indicating a potential upside of 4,029.63%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Organogenesis.
Cassava Sciences has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Cassava Sciences' return on equity.
Organogenesis has higher revenue and earnings than Cassava Sciences. Organogenesis is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Organogenesis beats Cassava Sciences on 11 of the 16 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SAVA) was last updated on 2/21/2025 by MarketBeat.com Staff
Free SAVA Stock Alerts